Clinical trials: active, sponsored by Royal Marsden NHS Foundation Trust
Breast Cancer
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery.
- Trial name
- Safe-De (NCT05058183)
- Testing
- ctDNA
- Where
- 13 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Cancer, Gastro-oesophageal Adenocarcinoma
Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the Young
This study aims to better understand how gastrointestinal (digestive system) cancers develop and how they respond to treatment in young adults, in order to improve ways to prevent, diagnose, and manage these cancers in this age…
- Conditions
- Colorectal Cancer, Gastro-oesophageal Adenocarcinoma, Hepato-Biliary Carcinoma in Situ Nos
- Trial name
- CLARITY (NCT07903571)
- Testing
- Research blood samples
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Endometrial Carcinoma (EC)
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
The goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in…
- Trial name
- SHORTEN (NCT07675733)
- Testing
- Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early…
- Trial name
- PRISON-UK (NCT07870707)
- Where
- United Kingdom
- Volunteers
- 9,007 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Triple Negative Breast Cancer, Locally Advanced Breast Cancer
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab.
- Conditions
- Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer
- Trial name
- PAveMenT (NCT04360941)
- Testing
- Palbociclib, Avelumab
- Where
- 9 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Patient and Provider Perspectives on Genetic Risk Profiling
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice.
- Trial name
- PPP (NCT07741929)
- Testing
- Qualitative interview
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Cancer
A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer
Pain from advanced pancreatic cancer is often difficult to control. This pain commonly occurs when the cancer affects a network of nerves in the abdomen called the coeliac plexus.
- Trial name
- PANCPLEX (NCT07689955)
- Testing
- IMRT
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST)
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer
- Trial name
- CURTAIN (NCT07673861)
- Testing
- Marsden360 ctDNA test and GTAB review
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours.
- Trial name
- HyPeR (NCT02998567)
- Testing
- Guadecitabine, Pembrolizumab, ASTX727
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Triple Negative Breast Cancer
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer, HER2+ Breast Cancer
- Trial name
- BELIEVE (NCT06681064)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Breast Cancer, ER+ Breast Cancer
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Analysis of circulating tumour DNA (ctDNA) found in a patient's peripheral blood can identify cancer progression and predict a patient's response to therapy.
- Conditions
- Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- FAIM (NCT04920708)
- Testing
- Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg
- Where
- 13 sites in United Kingdom
- Volunteers
- 57 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT).
- Trial name
- DESTINATION 2 (NCT06638541)
- Testing
- Prostate radical radiotherapy
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Metastatic Breast Cancer
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
- Trial name
- FORTITUDE (NCT07084571)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Sarcoma, Sarcoma, Leiomyo-, Adult
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma…
- Conditions
- Sarcoma, Sarcoma, Leiomyo-, Adult, Sarcoma, Synovial, Adult, Soft Tissue Sarcoma (STS)
- Trial name
- PANTHR-S (NCT07432932)
- Testing
- Observational Translational Study
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Cancer
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
The RESCUE study is a combined retrospective and prospective multicentre cohort study investigating the survival and functional outcomes in patients undergoing salvage surgery for recurrent, residual, and new primary head and…
- Trial name
- RESCUE (NCT05808920)
- Testing
- Molecular Analyses
- Where
- 9 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Squamous Cell Carcinoma of the Oropharynx
Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck.
- Trial name
- MOSES (NCT04151134)
- Testing
- Step serial sectioning histological processing
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon.
- Trial name
- INCLUDE PC (NCT07407686)
- Testing
- Surveys, Semi-structured interviews and focus groups
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Cancer
Exploratory Study of Clonal Evolution in Cancer for Patients Undergoing Transoral Robotic Surgery for Radiation Exposed Residual/reCurrent Tumours of the Upper Aerodigestive Tract
Radical radiotherapy for head and neck squamous cell cancer (HNSCC) can be administered to primary disease with curative intent. Residual disease, recurrence or further tumours may subsequently occur in this irradiated field.
- Trial name
- RECUT Plus (NCT04671940)
- Testing
- DNA Analysis
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Head Cancer Neck
IReC-Bio and IReC Registry
IReC is the world's first centre for recurrent head and neck cancers. We have the ambitious aim to create a centre of international excellence and set international standards in the curative treatment of recurrent head and neck…
- Trial name
- IReC-Bio (NCT05885490)
- Volunteers
- 10,000,000 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Prostate Cancer (Diagnosis)
Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise
Patients diagnosed with prostate cancer and receiving hormone therapy in conjunction with radiotherapy are likely to suffer from adverse effects caused by ADT treatment either short term or long term.
- Trial name
- ADHERE (NCT07243834)
- Testing
- Participation in a digital exercise intervention with virtual supervised group exercise sessions
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Royal Marsden NHS Foundation Trust